Medicine agency: Roche did not report side effects

June 22, 2012 by MARIA CHENG

(AP) — The European Medicines Agency is investigating "deficiencies" in the way drug maker Roche reported possible side effects in patients in the U.S., though it said there was no evidence patients are at risk.

European authorities spotted the problems during a routine inspection of Roche by British regulators in May. They noticed about 80,000 reports of possible side effects for medicines sold in the U.S. had not been analyzed to see if they were truly suspected adverse effects that needed to be reported. The reports were collected in a patient program that helps people deal with health insurance issues in the U.S., like reimbursement for medicines. Dozens of drugs were involved, including many cancer drugs.

In the reports of possible side effects, there were more than 15,000 deaths. The European Medicines Agency said it was unclear whether those deaths were linked to any Roche medicines.

"The scale of it sounds big, but what is not known is how many of these deaths have already been reported in another way," said Monika Benstetter, an EMA spokeswoman. "We need to get to the bottom of this."

Drug agencies regularly track side effects of drugs on the market since rare adverse events might not have been picked up during clinical trials when only limited numbers of people are exposed to the medicines.

Roche AG acknowledged it did not fully comply with regulations on the reporting system and that it was working "to address this matter expeditiously." Possible side effects picked up by the patient support program were not sent to Roche's own database for evaluation and therefore never made it to health officials, according to spokesman Daniel Grotzky. He said both minor and serious side effects were reported but could not provide further details.

"This was not intentional but of course it's not something that should have happened," Grotzky said. "We're looking into all of these cases and we will work with health authorities to update them." He said preliminary numbers had been given to health authorities about the potential number of missed adverse events and that measures would be taken to update their database. Grotzky said they hoped to have final numbers by January.

The EMA has given Roche until Wednesday to submit a detailed plan on how they will evaluate and report all outstanding cases, including how such problems will be corrected in the future.

"Based on the information we have, there is no need for patients to change their treatment," Benstetter said. "But we need more evidence that these deficiencies are being addressed."

Explore further: Roche probed over faulty drug-safety reporting

shares

Related Stories

Roche probed over faulty drug-safety reporting

June 21, 2012
Swiss pharmaceutical giant Roche is under investigation over a failure to properly report adverse drug side-effects, the European Medicines Agency (EMA) said on Thursday.

Effects of Tamiflu still uncertain, warn experts, as Roche continues to withhold key trial data

January 18, 2012
Two years after pharmaceutical giant Roche promised the BMJ it would release key Tamiflu trial data for independent scrutiny, the safety and effectiveness of this anti-influenza drug remains uncertain, warn experts today.

Roche extends its hostile takeover bid for Illumina

February 27, 2012
Swiss pharmaceutical group Roche said Monday it is sticking by its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina and is extending it for a month.

Novartis drug investigated after 11 deaths

January 20, 2012
A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.

US revokes Roche's Avastin for breast cancer

November 18, 2011
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

Recommended for you

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.